DEPDC1 is required for cell cycle progression and motility in nasopharyngeal carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• DEP domain containing 1 (DEPDC1) is a novel cancer-related gene and a potential therapeutic target for bladder cancer.
• The role of DEPDC1 in nasopharyngeal carcinoma (NPC) remains largely unknown.
• Understanding DEPDC1's function in NPC is crucial for developing new treatment strategies.

Purpose of the Study:

• To investigate the functional involvement of DEPDC1 in nasopharyngeal carcinoma (NPC).
• To evaluate the therapeutic potential of targeting DEPDC1 in NPC.
• To elucidate the molecular mechanisms underlying DEPDC1's role in NPC progression.

Main Methods:

• Quantitative real-time PCR and Western blotting to assess DEPDC1 expression in NPC tissues and cell lines.
• siRNA-mediated DEPDC1 depletion to study its effects on NPC cell proliferation, cell cycle, migration, and invasion.
• Indirect immunofluorescence assays to analyze mitotic defects.
• Analysis of NF-κB pathway signaling components and downstream target genes.
• In vivo studies using NPC xenograft nude mouse models.

Main Results:

• DEPDC1 was significantly overexpressed in NPC tissues compared to normal tissues.
• DEPDC1 depletion inhibited NPC cell proliferation, induced cell cycle arrest, and promoted apoptosis.
• Knockdown of DEPDC1 reduced NPC cell migration and invasion.
• DEPDC1 knockdown modulated the NF-κB pathway, affecting key genes involved in proliferation, tumorigenesis, and metastasis.
• In vivo studies confirmed that DEPDC1 knockdown inhibited tumor growth in NPC xenografts.

Conclusions:

• DEPDC1 is essential for cell cycle progression and motility in NPC cells.
• DEPDC1 plays a significant role in NPC tumorigenesis and metastasis.
• DEPDC1 represents a promising novel therapeutic target for nasopharyngeal carcinoma.